Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
University of Vermont Medical Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07494448CT.gov Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07648914CT.gov A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) | — | Not Yet Recruiting | — | — | — |
NCT07406542CT.gov A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07417241CT.gov SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study | — | Not Yet Recruiting | — | — | — |
NCT07461454CT.gov YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT07340541CT.gov Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies | — | Recruiting | — | — | — |
NCT06875128CT.gov Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease | — | Recruiting | — | — | — |
NCT07540533CT.gov A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT07366840CT.gov RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure | — | Not Yet Recruiting | — | — | — |
NCT07222215CT.gov PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) | — | Recruiting | — | — | — |
Show 292 more trialsShow fewer
NCT07007559CT.gov ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer | — | Recruiting | — | — | — |
NCT07112053CT.gov A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer | — | Recruiting | — | — | — |
NCT07467330CT.gov Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment | — | Recruiting | — | — | — |
NCT07161791CT.gov Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07071337CT.gov A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy | — | Recruiting | — | — | — |
NCT07019337CT.gov Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07021261CT.gov Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients | — | Not Yet Recruiting | — | — | — |
NCT06957886CT.gov A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT06992336CT.gov Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy | — | Recruiting | — | — | — |
NCT06797635CT.gov Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | — | Recruiting | — | — | — |
NCT06105684CT.gov Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT06602167CT.gov Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome | — | Recruiting | — | — | — |
NCT06568692CT.gov A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT06102824CT.gov Organoid-based Functional Precision Therapy for Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT05933395CT.gov Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor | — | Recruiting | — | — | — |
NCT06162663CT.gov Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors | — | Terminated | — | — | — |
NCT06409390CT.gov Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | — | Recruiting | — | — | — |
NCT06247995CT.gov A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | — | Recruiting | — | — | — |
NCT06561607CT.gov A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06483386CT.gov Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06383767CT.gov A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT06598046CT.gov A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC | — | Recruiting | — | — | — |
NCT06458413CT.gov Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT06324357CT.gov Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | — | Recruiting | — | — | — |
NCT05919108CT.gov Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers | — | Recruiting | — | — | — |
NCT06339281CT.gov A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06268327CT.gov Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy | — | Not Yet Recruiting | — | — | — |
NCT06229067CT.gov Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06018337CT.gov A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | — | Active Not Recruiting | — | — | — |
NCT06268652CT.gov Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer | — | Recruiting | — | — | — |
NCT06375707CT.gov Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer | — | Unknown | — | — | — |
NCT06217185CT.gov The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | — | Recruiting | — | — | — |
NCT06176534CT.gov Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial | — | Recruiting | — | — | — |
NCT06079983CT.gov JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects | — | Recruiting | — | — | — |
NCT06152822CT.gov Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases | — | Unknown | — | — | — |
NCT06156761CT.gov Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer | — | Unknown | — | — | — |
NCT06112379CT.gov A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT06081959CT.gov Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT06099769CT.gov A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT06143553CT.gov Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT05845138CT.gov A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression. | — | Unknown | — | — | — |
NCT04901299CT.gov Fulvestrant + Neratinib In Breast Cancer | — | Withdrawn | — | — | — |
NCT05814354CT.gov SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial | — | Recruiting | — | — | — |
NCT06035016CT.gov Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer | — | Recruiting | — | — | — |
NCT05876065CT.gov Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT05861271CT.gov Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer | — | Recruiting | — | — | — |
NCT05840211CT.gov Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy | — | Active Not Recruiting | — | — | — |
NCT05774886CT.gov Implantable Microdevice for TNBC - Pilot Study | — | Withdrawn | — | — | — |
NCT06202261CT.gov A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT04789096CT.gov Tucatinib Together With Pembrolizumab and Trastuzumab | — | Terminated | — | — | — |
NCT05953909CT.gov A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01). | — | Unknown | — | — | — |
NCT05238831CT.gov SMMART Adaptive Clinical Treatment (ACT) Trial | — | Withdrawn | — | — | — |
NCT06373744CT.gov Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients | — | Completed | — | — | — |
NCT05594095CT.gov SNF Platform Study of HR+/ HER2-advanced Breast Cancer | — | Recruiting | — | — | — |
NCT05388149CT.gov Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease | — | Recruiting | — | — | — |
NCT05629585CT.gov A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | — | Active Not Recruiting | — | — | — |
NCT05411380CT.gov Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor. | — | Unknown | — | — | — |
NCT05491057CT.gov Treatment Patterns of Neratinib in HER2+ EBC in China | — | Not Yet Recruiting | — | — | — |
NCT04965064CT.gov Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling | — | Recruiting | — | — | — |
NCT05252988CT.gov Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib | — | Active Not Recruiting | — | — | — |
NCT05243641CT.gov Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test | — | Terminated | — | — | — |
NCT05469750CT.gov Dalpiciclib Plus Letrozole and Capecitabine | — | Unknown | — | — | — |
NCT04886531CT.gov Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | — | Recruiting | — | — | — |
NCT05374512CT.gov A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) | — | Active Not Recruiting | — | — | — |
NCT05227131CT.gov Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT05131893CT.gov Neoadjuvant Treatment of Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT05172518CT.gov Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT05163223CT.gov Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer | — | Terminated | — | — | — |
NCT06313983CT.gov A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT05747326CT.gov Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer | — | Unknown | — | — | — |
NCT04856475CT.gov Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer | — | Withdrawn | — | — | — |
NCT05104866CT.gov A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | — | Active Not Recruiting | — | — | — |
NCT05063136CT.gov Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer | — | Recruiting | — | — | — |
NCT05063786CT.gov Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | — | Active Not Recruiting | — | — | — |
NCT04849364CT.gov Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer | — | Terminated | — | — | — |
NCT04383275CT.gov Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS) | — | Recruiting | — | — | — |
NCT04965688CT.gov Biology Guided Therapy for Breast Cancer for ER Positive | — | Terminated | — | — | — |
NCT05292742CT.gov Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer | — | Recruiting | — | — | — |
NCT04922008CT.gov Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D) | — | Not Yet Recruiting | — | — | — |
NCT04721977CT.gov A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001) | — | Active Not Recruiting | — | — | — |
NCT04803539CT.gov A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC | — | Recruiting | — | — | — |
NCT06015100CT.gov Efficacy and Safety of Inetetamab Plus Pyrotiniband and Capecitabine in HER2-positive Metastatic Breast Cancer Patients With or Without Brain Metastasis | — | Unknown | — | — | — |
NCT04556773CT.gov A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04780347CT.gov Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer | — | Unknown | — | — | — |
NCT04639986CT.gov Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | — | Active Not Recruiting | — | — | — |
NCT05052437CT.gov PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer | — | Completed | — | — | — |
NCT04646759CT.gov Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT04400695CT.gov A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 | — | Unknown | — | — | — |
NCT04509596CT.gov DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer | — | Completed | — | — | — |
NCT04681911CT.gov Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT04494425CT.gov Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04274933CT.gov A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy | — | Terminated | — | — | — |
NCT04355858CT.gov Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | — | Unknown | — | — | — |
NCT04389073CT.gov Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine | — | Unknown | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04276493CT.gov Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab | — | Completed | — | — | — |
NCT04158258CT.gov A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America | — | Active Not Recruiting | — | — | — |
NCT04262804CT.gov A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC | — | Unknown | — | — | — |
NCT04246502CT.gov Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT04335669CT.gov NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC | — | Active Not Recruiting | — | — | — |
NCT04905667CT.gov Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ® | — | Completed | — | — | — |
NCT03997968CT.gov A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | — | Completed | — | — | — |
NCT04095390CT.gov A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer | — | Unknown | — | — | — |
NCT03818685CT.gov Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease | — | Unknown | — | — | — |
NCT04001621CT.gov Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer | — | Unknown | — | — | — |
NCT03812393CT.gov Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast | — | Unknown | — | — | — |
NCT03901339CT.gov Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer | — | Completed | — | — | — |
NCT03923166CT.gov Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer | — | Unknown | — | — | — |
NCT03853707CT.gov Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT03775525CT.gov Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer | — | Unknown | — | — | — |
NCT04350021CT.gov Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer | — | Completed | — | — | — |
NCT03839823CT.gov Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT03501979CT.gov Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD | — | Terminated | — | — | — |
NCT03858972CT.gov Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC | — | Terminated | — | — | — |
NCT03473639CT.gov A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy | — | Completed | — | — | — |
NCT04258163CT.gov Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy | — | Completed | — | — | — |
NCT03734029CT.gov Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | — | Active Not Recruiting | — | — | — |
NCT03647514CT.gov Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer | — | Unknown | — | — | — |
NCT03094052CT.gov Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib | — | Completed | — | — | — |
NCT04012918CT.gov Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study | — | Unknown | — | — | — |
NCT03523585CT.gov DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] | — | Completed | — | — | — |
NCT05833919CT.gov Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients | — | Unknown | — | — | — |
NCT03462251CT.gov Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line | — | Completed | — | — | — |
NCT03424005CT.gov A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT03383679CT.gov Study on Androgen Receptor and Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT03101748CT.gov Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | — | Terminated | — | — | — |
NCT03326674CT.gov Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC | — | Terminated | — | — | — |
NCT03377387CT.gov Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03507465CT.gov Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer | — | Unknown | — | — | — |
NCT02574455CT.gov Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) | — | Completed | — | — | — |
NCT03289039CT.gov Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT03322215CT.gov HR+/HER2- Advanced Breast Cancer and Endocrine Resistance | — | Terminated | — | — | — |
NCT03044730CT.gov Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery | — | Unknown | — | — | — |
NCT03084939CT.gov Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02754011CT.gov Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative | — | Completed | — | — | — |
NCT03182634CT.gov The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial | — | Unknown | — | — | — |
NCT02673398CT.gov Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer | — | Completed | — | — | — |
NCT02955940CT.gov An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | — | Active Not Recruiting | — | — | — |
NCT02592746CT.gov A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC | — | Unknown | — | — | — |
NCT03006614CT.gov PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer | — | Unknown | — | — | — |
NCT02491697CT.gov Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02664103CT.gov Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer | — | Completed | — | — | — |
NCT02650752CT.gov Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases | — | Completed | — | — | — |
NCT02344472CT.gov Detect V / CHEVENDO (Chemo vs. Endo) | — | Active Not Recruiting | — | — | — |
NCT02947061CT.gov S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer | — | Unknown | — | — | — |
NCT02338245CT.gov Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab | — | Completed | — | — | — |
NCT02934828CT.gov Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer | — | Unknown | — | — | — |
NCT02248571CT.gov Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab | — | Completed | — | — | — |
NCT01782651CT.gov Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients | — | Completed | — | — | — |
NCT02361112CT.gov Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02253459CT.gov Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02236000CT.gov A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer | — | Completed | — | — | — |
NCT02213744CT.gov MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | — | Terminated | — | — | — |
NCT02000882CT.gov STAR Cape+BKM120 MBC With Brain Met | — | Completed | — | — | — |
NCT02120417CT.gov A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer | — | Terminated | — | — | — |
NCT02028507CT.gov Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors | — | Completed | — | — | — |
NCT02842099CT.gov Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer | — | Unknown | — | — | — |
NCT02207335CT.gov Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer | — | Unknown | — | — | — |
NCT01349088CT.gov Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01875367CT.gov Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer | — | Completed | — | — | — |
NCT01950182CT.gov Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer | — | Completed | — | — | — |
NCT01843725CT.gov Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers | — | Completed | — | — | — |
NCT01953003CT.gov Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | — | Completed | — | — | — |
NCT01939054CT.gov Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients | — | Unknown | — | — | — |
NCT01873833CT.gov Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01783756CT.gov Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | — | Completed | — | — | — |
NCT01887288CT.gov Capecitabine With Digoxin for Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT02210364CT.gov Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). | — | Completed | — | — | — |
NCT01783444CT.gov A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. | — | Completed | — | — | — |
NCT01702558CT.gov A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC) | — | Terminated | — | — | — |
NCT01802970CT.gov Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients | — | Completed | — | — | — |
NCT01640665CT.gov Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors | — | Completed | — | — | — |
NCT01941771CT.gov Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01609127CT.gov Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT01494662CT.gov HKI-272 for HER2-Positive Breast Cancer and Brain Metastases | — | Completed | — | — | — |
NCT01471847CT.gov A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab | — | Completed | — | — | — |
NCT01655992CT.gov A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC) | — | Terminated | — | — | — |
NCT01290718CT.gov A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy. | — | Terminated | — | — | — |
NCT01526512CT.gov Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT04175171CT.gov Clinical Trial of Comparative Study of GB221 Pharmacokinetics | — | Completed | — | — | — |
NCT01439282CT.gov Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer | — | Completed | — | — | — |
NCT01300962CT.gov Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01326481CT.gov Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01501669CT.gov Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT01423123CT.gov Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer | — | Completed | — | — | — |
NCT01380808CT.gov Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC) | — | Completed | — | — | — |
NCT01231802CT.gov Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT00964704CT.gov A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT01234402CT.gov Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients | — | Completed | — | — | — |
NCT01234337CT.gov Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer | — | Completed | — | — | — |
NCT01498458CT.gov Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01008150CT.gov Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | — | Completed | — | — | — |
NCT01238029CT.gov Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01233505CT.gov Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT01131195CT.gov Metronomic Therapy in Metastatic Breast Cancer. | — | Completed | — | — | — |
NCT01156753CT.gov A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer | — | Completed | — | — | — |
NCT01158274CT.gov RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | — | Completed | — | — | — |
NCT01195298CT.gov Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT01132664CT.gov Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer | — | Terminated | — | — | — |
NCT01387295CT.gov Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease | — | Completed | — | — | — |
NCT01111825CT.gov Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT01387373CT.gov Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer | — | Completed | — | — | — |
NCT01067989CT.gov Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01415336CT.gov AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer | — | Unknown | — | — | — |
NCT01042379CT.gov I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | — | Recruiting | — | — | — |
NCT01323530CT.gov A Confirmation Study of Eribulin in Combination With Capecitabine | — | Completed | — | — | — |
NCT01077726CT.gov A Study of Xeloda (Capecitabine) in Breast Cancer Patients With Central Nervous System (CNS) Progression | — | Completed | — | — | — |
NCT01262469CT.gov Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer. | — | Completed | — | — | — |
NCT00959946CT.gov Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00915018CT.gov Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer | — | Completed | — | — | — |
NCT00885755CT.gov A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00878709CT.gov Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer | — | Completed | — | — | — |
NCT00929240CT.gov A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01200212CT.gov A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01095003CT.gov Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer | — | Completed | — | — | — |
NCT00845910CT.gov A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00967031CT.gov Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases | — | Completed | — | — | — |
NCT00807859CT.gov Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00777101CT.gov Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | — | Completed | — | — | — |
NCT00829166CT.gov A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01227408CT.gov Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer | — | Withdrawn | — | — | — |
NCT01180335CT.gov Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer | — | Completed | — | — | — |
NCT00741260CT.gov Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer | — | Completed | — | — | — |
NCT00661102CT.gov A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine). | — | Completed | — | — | — |
NCT00811135CT.gov A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer | — | Completed | — | — | — |
NCT00795678CT.gov Chemotherapeutic Agents in Brain/Breast | — | Completed | — | — | — |
NCT00684983CT.gov Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer | — | Completed | — | — | — |
NCT00721630CT.gov Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00634088CT.gov Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | — | Terminated | — | — | — |
NCT00632489CT.gov LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients | — | Completed | — | — | — |
NCT00717951CT.gov A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer | — | Unknown | — | — | — |
NCT00708903CT.gov Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization) | — | Completed | — | — | — |
NCT00706030CT.gov Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00600340CT.gov 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab | — | Completed | — | — | — |
NCT00657137CT.gov APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202) | — | Terminated | — | — | — |
NCT00568022CT.gov A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00479856CT.gov Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer | — | Terminated | — | — | — |
NCT00576901CT.gov A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer. | — | Terminated | — | — | — |
NCT00462865CT.gov Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse | — | Terminated | — | — | — |
NCT00473005CT.gov Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast | — | Terminated | — | — | — |
NCT00629148CT.gov Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC) | — | Completed | — | — | — |
NCT00496366CT.gov Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer | — | Terminated | — | — | — |
NCT00508274CT.gov Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China | — | Terminated | — | — | — |
NCT00452673CT.gov Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00477464CT.gov Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00493636CT.gov 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy | — | Completed | — | — | — |
NCT00437073CT.gov Brain Metastases In ErbB2-Positive Breast Cancer | — | Terminated | — | — | — |
NCT00437294CT.gov Enzastaurin in Combination of Capecitabine to Treat Breast Cancer | — | Terminated | — | — | — |
NCT00450515CT.gov Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT00433589CT.gov Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes | — | Completed | — | — | — |
NCT00337103CT.gov E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | — | Completed | — | — | — |
NCT00589901CT.gov An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC) | — | Unknown | — | — | — |
NCT00327743CT.gov Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00532714CT.gov Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC | — | Completed | — | — | — |
NCT00397761CT.gov Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer | — | Withdrawn | — | — | — |
NCT00338247CT.gov EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer | — | Approved For Marketing | — | — | — |
NCT01196455CT.gov Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT00305643CT.gov Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer | — | Terminated | — | — | — |
NCT02005549CT.gov A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer | — | Completed | — | — | — |
NCT00265733CT.gov Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00266799CT.gov The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071) | — | Completed | — | — | — |
NCT00227656CT.gov Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer | — | Terminated | — | — | — |
NCT00127933CT.gov XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer | — | Completed | — | — | — |
NCT00194792CT.gov Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer | — | Terminated | — | — | — |
NCT00618124CT.gov A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together | — | Completed | — | — | — |
NCT00204776CT.gov XELOX for Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00155259CT.gov Docetaxel, Cisplatin and Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT00196872CT.gov A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN) | — | Completed | — | — | — |
NCT00087152CT.gov S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00196859CT.gov Study in Elderly Patients With Early Breast Cancer (ICE) | — | Completed | — | — | — |
NCT00077363CT.gov Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00665457CT.gov Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery | — | Terminated | — | — | — |
NCT00081796CT.gov Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00082095CT.gov To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older | — | Terminated | — | — | — |
NCT00078572CT.gov Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00082433CT.gov Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00225056CT.gov Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma | — | Terminated | — | — | — |
NCT00068588CT.gov GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00070252CT.gov Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer | — | Completed | — | — | — |
NCT00080301CT.gov Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00198237CT.gov Genomic & Proteomic Analysis of Docetaxel & Capecitabine as Primary Chemo for Stage II-III Breast Cancer | — | Completed | — | — | — |
NCT00263705CT.gov Adjuvant Capecitabine in Elderly Patients With Breast Cancer: a Phase II Study | — | Completed | — | — | — |
NCT00214864CT.gov A Study of Weekly Taxotere and Xeloda in Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00049244CT.gov BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT00544765CT.gov Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer | — | Completed | — | — | — |
NCT00089479CT.gov A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer | — | Completed | — | — | — |
NCT00352378CT.gov Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer | — | Completed | — | — | — |
NCT00153907CT.gov Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02748213CT.gov A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00193102CT.gov Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00005908CT.gov Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capecitabine (this asset) | University of Vermont Medical Center | Approved | BB · 67 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Capecitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Carcinoma | — | P4 | BBB · 73 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Capecitabine in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/capecitabine-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →